BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era

Leuk Lymphoma. 2016 Sep;57(9):2199-203. doi: 10.3109/10428194.2015.1126588. Epub 2016 Jan 14.

Affiliations

¹ a 2nd Department of Internal Medicine, Propaedeutic , Hematology Unit, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University General Hospital , Haidari , Greece ;
² b Department of Biochemistry and Molecular Biology , University of Athens , Athens , Greece ;
³ c 2nd Department of Pathology, School of Medicine , National and Kapodistrian University of Athens, "Attikon" University Hospital , Haidari , Greece.

PMID: 27442703
DOI: 10.3109/10428194.2015.1126588

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Pharmacological / metabolism
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Gene Expression Regulation, Neoplastic
HL-60 Cells
Humans
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / genetics
Lymphoma, Large B-Cell, Diffuse / mortality
Muscle Proteins / genetics*
Muscle Proteins / metabolism
Prognosis
Proto-Oncogene Proteins c-bcl-2 / genetics*
Proto-Oncogene Proteins c-bcl-2 / metabolism
Rituximab / administration & dosage
Rituximab / therapeutic use*
Survival Analysis
Treatment Outcome
Up-Regulation / genetics

Substances

BCL2L12 protein, human
Biomarkers, Pharmacological
Biomarkers, Tumor
Muscle Proteins
Proto-Oncogene Proteins c-bcl-2
Rituximab